

A Message from Our CEO

Building Upon Our Strong Foundation to Advance Access for Patients



Viatriis marked an important inflection point in its evolution in 2024, and I am very proud of what our dedicated and passionate colleagues across the world collectively accomplished. Together, we progressed on important commitments, strengthened our foundation, worked with our partners in the global health community to supply high-quality medicines to approximately 1 billion¹ patients globally, and delivered on our strategy to develop and provide more innovative medicines to help address unmet medical needs.

We completed our divestitures to simplify and streamline our business, grew our base business, and delivered new product revenues of \$582 million. In addition, we retired approximately \$3.7 billion of debt while also returning capital to our shareholders. These accomplishments position us to maintain a diversified base business - supporting healthcare systems around the world today, while also investing in an expanding innovative portfolio for tomorrow.

Viatriis' mission to empower people worldwide to live healthier at every stage of life is as relevant as ever. Our greatest contribution to this effort in 2024 was the unique way we approach building access to medicine at scale and supporting health systems across the world. The opportunity to address unmet medical needs and affect human health is remarkable and inspiring, and we are eager to make more innovative treatments accessible.

How we conduct ourselves impacts our ability to make progress on our mission, so we work systematically to advance sustainable and responsible practices, and we remain committed to the UNGC 10 principles on human rights, labor, the environment, and anti-corruption.

Throughout the year, we made progress on several priority areas with regards to reducing our environmental impact, continuing to build our culture, further strengthening the health and safety of our colleagues, and scaling access to wellbeing resources for all colleagues around the globe. We are honored to have been recognized for our work in 2024 by being named Time Magazine's World's Most Sustainable Companies 2024, USA Today's America's Climate Leaders 2024, Forbes Top Companies for Women 2024 and Forbes Best Employers 2024.

Looking forward, 2025 is an important year from a scientific execution perspective. We anticipate more than 100 submissions for a number of medicines, including complex injectables that we have been steadily and strategically developing. These are difficult-to-develop and difficult-to-manufacture medicines, and we are proud of the scientific and development expertise we have built in this area. In addition, we have 11 Phase 3 programs across our pipeline, we are expecting six Phase 3 data readouts this year and several important late-stage development milestones for our innovative assets - selatogrel, cenerimod and sotagliflozin.

Another significant priority for our company is our ongoing remediation work at our Indore, India, oral finished dose manufacturing facility. I appreciate the collective efforts by everyone involved to mitigate any supply disruptions and continue to meet the needs of the patients we serve.

In closing, I want to thank all our colleagues around the world for their continued dedication to our mission and to striving to meet the needs of our many stakeholders. With the passion of our colleagues and our robust global scope, our company is well positioned to continue to advance access and meet patient needs for many years to come.

Scott A. Smith

Chief Executive Officer, Viatriis

A Message from our Chair of the Board



It is a privilege to serve as Chair of the Board of Directors for a company that holds such a relevant role in the global health community. Together with its partners across the world, Viatriis is proud to support healthcare systems and patients in their pursuit of living healthier at every stage of life.

The board and I remain committed to Viatriis' mission and to overseeing management's continued advancement of sustainable and responsible practices. We express our sincere appreciation to all members of Viatriis' dedicated and highly competent workforce, each of whom make invaluable contributions as the company strives to enhance its ability to provide sustainable access to medicine.

Melina Higgins

Chair of the Board of Directors, Viatriis

Sources

¹See page 4 for more information about number of patients served.